January 22, 2018
Rose
The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.
from Health http://ift.tt/2Dusfn4
January 22, 2018
Rose
Health, Health - The New York Times
No comments
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment